{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:06:04Z","timestamp":1793833564714,"version":"4.6.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"European Research Council (ERC) under the European Union\u2019s Horizon 2020 research and innovation program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal genetic landscapes, and consistently share key genetic alterations, mirroring tumor evolution in longitudinal sampling. Our drug screening pipeline is implemented using PDOs, testing standard-of-care and FDA-approved compounds for other tumors. Integrative analysis of drug response profiles with matched PDO genomic analysis is used to determine enrichment thresholds for candidate markers of therapy response and resistance. Finally, by assessing the clinical history of longitudinally sampled cases, we can determine whether the disease clonal evolution matched with drug response.<\/jats:p>","DOI":"10.1038\/s41467-023-37696-2","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T12:03:32Z","timestamp":1681819412000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":111,"title":["Bladder cancer organoids as a functional system to model different disease stages and therapy response"],"prefix":"10.1038","volume":"14","author":[{"given":"Martina","family":"Minoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Cantore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0665-8607","authenticated-orcid":false,"given":"Daniel","family":"Hanhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1126-0476","authenticated-orcid":false,"given":"Mirjam","family":"Kiener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarcisio","family":"Fedrizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3644-8395","authenticated-orcid":false,"given":"Federico","family":"La Manna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1716-5237","authenticated-orcid":false,"given":"Sofia","family":"Karkampouna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1527-3151","authenticated-orcid":false,"given":"Panagiotis","family":"Chouvardas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Genitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2744-2381","authenticated-orcid":false,"given":"Antonio","family":"Rodriguez-Calero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Comp\u00e9rat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Klima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Gasperini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3529-2088","authenticated-orcid":false,"given":"Roland","family":"Seiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8266-8631","authenticated-orcid":false,"given":"Francesca","family":"Demichelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George N.","family":"Thalmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6085-7706","authenticated-orcid":false,"given":"Marianna","family":"Kruithof-de Julio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,18]]},"reference":[{"key":"37696_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.eururo.2017.04.015","volume":"72","author":"V Soukup","year":"2017","unstructured":"Soukup, V. et al. Prognostic performance and reproducibility of the 1973 and 2004\/2016 World Health Organization grading classification systems in non-muscle-invasive bladder cancer: a European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel systematic review. Eur. Urol. 72, 801\u2013813 (2017).","journal-title":"Eur. Urol."},{"key":"37696_CR2","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","volume":"76","author":"M Babjuk","year":"2019","unstructured":"Babjuk, M. et al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u20142019 update. Eur. Urol. 76, 639\u2013657 (2019).","journal-title":"Eur. Urol."},{"key":"37696_CR3","first-page":"43","volume":"22","author":"RS Matulewicz","year":"2020","unstructured":"Matulewicz, R. S. & Steinberg, G. D. Non-muscle-invasive bladder cancer: overview and contemporary treatment landscape of neoadjuvant chemoablative therapies. Rev. Urol. 22, 43\u201351 (2020).","journal-title":"Rev. Urol."},{"key":"37696_CR4","first-page":"271","volume":"66","author":"KD Miller","year":"2016","unstructured":"Miller, K. D. et al. Cancer treatment and survivorship statistics, 2016. CA: A Cancer J. Clin. 66, 271\u2013289 (2016).","journal-title":"CA: A Cancer J. Clin."},{"key":"37696_CR5","first-page":"11536","volume":"24","author":"G Facchini","year":"2020","unstructured":"Facchini, G. et al. Advanced\/metastatic bladder cancer: current status and future directions. Eur. Rev. Med. Pharm. Sci. 24, 11536\u201311552 (2020).","journal-title":"Eur. Rev. Med. Pharm. Sci."},{"key":"37696_CR6","doi-asserted-by":"publisher","unstructured":"Witjes, J. A. et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur. Urol. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.055 (2020).","DOI":"10.1016\/j.eururo.2020.03.055"},{"key":"37696_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.eururo.2014.09.007","volume":"67","author":"H Zargar","year":"2015","unstructured":"Zargar, H. et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur. Urol. 67, 241\u2013249 (2015).","journal-title":"Eur. Urol."},{"key":"37696_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi, W. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25, 152\u2013165 (2014).","journal-title":"Cancer Cell"},{"key":"37696_CR9","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","volume":"18","author":"G Sj\u00f6dahl","year":"2012","unstructured":"Sj\u00f6dahl, G. et al. A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res. 18, 3377\u20133386 (2012).","journal-title":"Clin. Cancer Res."},{"key":"37696_CR10","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1073\/pnas.1318376111","volume":"111","author":"JS Damrauer","year":"2014","unstructured":"Damrauer, J. S. et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc. Natl Acad. Sci. USA 111, 3110\u20133115 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"37696_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"Cancer Genome Atlas Research Network.","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315\u2013322 (2014).","journal-title":"Nature"},{"key":"37696_CR12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","volume":"173","author":"SH Lee","year":"2018","unstructured":"Lee, S. H. et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell 173, 515\u2013528.e17 (2018).","journal-title":"Cell"},{"key":"37696_CR13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.cell.2014.11.050","volume":"160","author":"M Huch","year":"2015","unstructured":"Huch, M. et al. Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell 160, 299\u2013312 (2015).","journal-title":"Cell"},{"key":"37696_CR14","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-18-0474","volume":"8","author":"SJ Hill","year":"2018","unstructured":"Hill, S. J. et al. Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids. Cancer Disco. 8, 1404\u20131421 (2018).","journal-title":"Cancer Disco."},{"key":"37696_CR15","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.1158\/1078-0432.CCR-18-3590","volume":"25","author":"CA Pasch","year":"2019","unstructured":"Pasch, C. A. et al. Patient-derived cancer organoid cultures to predict sensitivity to chemotherapy and radiation. Clin. Cancer Res. 25, 5376\u20135387 (2019).","journal-title":"Clin. Cancer Res."},{"key":"37696_CR16","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1158\/2159-8290.CD-16-1154","volume":"7","author":"C Pauli","year":"2017","unstructured":"Pauli, C. et al. Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Disco. 7, 462\u2013477 (2017).","journal-title":"Cancer Disco."},{"key":"37696_CR17","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","volume":"8","author":"H Tiriac","year":"2018","unstructured":"Tiriac, H. et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Disco. 8, 1112\u20131129 (2018).","journal-title":"Cancer Disco."},{"key":"37696_CR18","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis, G. et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359, 920\u2013926 (2018).","journal-title":"Science"},{"key":"37696_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.stem.2019.10.010","volume":"26","author":"Y Yao","year":"2020","unstructured":"Yao, Y. et al. Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer. Cell Stem Cell 26, 17\u201326.e6 (2020).","journal-title":"Cell Stem Cell"},{"key":"37696_CR20","doi-asserted-by":"publisher","first-page":"eaay2574","DOI":"10.1126\/scitranslmed.aay2574","volume":"11","author":"SN Ooft","year":"2019","unstructured":"Ooft, S. N. et al. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Sci. Transl. Med. 11, eaay2574 (2019).","journal-title":"Sci. Transl. Med."},{"key":"37696_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21300-6","volume":"12","author":"S Karkampouna","year":"2021","unstructured":"Karkampouna, S. et al. Patient-derived xenografts and organoids model therapy response in prostate cancer. Nat. Commun. 12, 1117 (2021).","journal-title":"Nat. Commun."},{"key":"37696_CR22","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","volume":"72","author":"EJ Pietzak","year":"2017","unstructured":"Pietzak, E. J. et al. Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets. Eur. Urol. 72, 952\u2013959 (2017).","journal-title":"Eur. Urol."},{"key":"37696_CR23","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540\u2013556.e25 (2017).","journal-title":"Cell"},{"key":"37696_CR24","doi-asserted-by":"publisher","unstructured":"Shariat, S. F. et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2004.03.118 (2016).","DOI":"10.1200\/JCO.2004.03.118"},{"key":"37696_CR25","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1158\/1535-7163.MCT-18-0510","volume":"18","author":"SL Fricke","year":"2019","unstructured":"Fricke, S. L. et al. MTORC1\/2 inhibition as a therapeutic strategy for PIK3CA mutant cancers. Mol. Cancer Ther. 18, 346\u2013355 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"37696_CR26","doi-asserted-by":"publisher","first-page":"e1248","DOI":"10.1002\/cti2.1248","volume":"10","author":"L Yu","year":"2021","unstructured":"Yu, L. et al. Patient-derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR-T cells in vitro. Clin. Transl. Immunol. 10, e1248 (2021).","journal-title":"Clin. Transl. Immunol."},{"key":"37696_CR27","doi-asserted-by":"publisher","first-page":"2103999","DOI":"10.1002\/advs.202103999","volume":"9","author":"Z Li","year":"2022","unstructured":"Li, Z. et al. Patient-derived upper tract urothelial carcinoma organoids as a platform for drug screening. Adv. Sci. 9, 2103999 (2022).","journal-title":"Adv. Sci."},{"key":"37696_CR28","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","volume":"172","author":"N Sachs","year":"2018","unstructured":"Sachs, N. et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell 172, 373\u2013386.e10 (2018).","journal-title":"Cell"},{"key":"37696_CR29","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1073\/pnas.1803595116","volume":"116","author":"J Mullenders","year":"2019","unstructured":"Mullenders, J. et al. Mouse and human urothelial cancer organoids: a tool for bladder cancer research. Proc. Natl Acad. Sci. USA 116, 4567\u20134574 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"37696_CR30","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.celrep.2019.03.088","volume":"27","author":"Y Saito","year":"2019","unstructured":"Saito, Y. et al. Establishment of patient-derived organoids and drug screening for biliary tract carcinoma. Cell Rep. 27, 1265\u20131276.e4 (2019).","journal-title":"Cell Rep."},{"key":"37696_CR31","doi-asserted-by":"publisher","unstructured":"Kamoun, A. et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol. https:\/\/doi.org\/10.1016\/j.eururo.2019.09.006 (2019).","DOI":"10.1016\/j.eururo.2019.09.006"},{"key":"37696_CR32","doi-asserted-by":"publisher","first-page":"623","DOI":"10.4111\/icu.20210265","volume":"62","author":"MA Han","year":"2021","unstructured":"Han, M. A. et al. Intravesical gemcitabine for non-muscle invasive bladder cancer: an abridged Cochrane Review. Investig. Clin. Urol. 62, 623\u2013630 (2021).","journal-title":"Investig. Clin. Urol."},{"key":"37696_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-020-00610-9","volume":"20","author":"R Li","year":"2020","unstructured":"Li, R. et al. Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial. BMC Urol. 20, 97 (2020).","journal-title":"BMC Urol."},{"key":"37696_CR34","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1001\/jama.2018.4657","volume":"319","author":"EM Messing","year":"2018","unstructured":"Messing, E. M. et al. Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial. JAMA 319, 1880\u20131888 (2018).","journal-title":"JAMA"},{"key":"37696_CR35","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/j.clgc.2019.09.005","volume":"18","author":"W Fukuokaya","year":"2020","unstructured":"Fukuokaya, W. et al. Effectiveness of intravesical doxorubicin immediately following resection of primary non-muscle-invasive bladder cancer: a propensity score-matched analysis. Clin. Genitourin. Cancer 18, e55\u2013e61 (2020).","journal-title":"Clin. Genitourin. Cancer"},{"key":"37696_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85151-3","volume":"11","author":"F Krentel","year":"2021","unstructured":"Krentel, F. et al. A showcase study on personalized in silico drug response prediction based on the genetic landscape of muscle invasive bladder cancer. Sci. Rep. 11, 5849 (2021).","journal-title":"Sci. Rep."},{"key":"37696_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/BLC-180196","volume":"5","author":"VS Koshkin","year":"2019","unstructured":"Koshkin, V. S., O\u2019Donnell, P., Yu, E. Y. & Grivas, P. Systematic Review: Targeting HER2 in bladder cancer. Bladder Cancer 5, 1\u201312 (2019).","journal-title":"Bladder Cancer"},{"key":"37696_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/srep42713","volume":"7","author":"B Kiss","year":"2017","unstructured":"Kiss, B. et al. Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy. Sci. Rep. 7, 42713 (2017).","journal-title":"Sci. Rep."},{"key":"37696_CR39","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/jjco\/hyd142","volume":"30","author":"M-H Yang","year":"2000","unstructured":"Yang, M.-H. et al. Single agent paclitaxel as a first-line therapy in advanced urothelial carcinoma: its efficacy and safety in patients even with pretreatment renal insufficiency. Jpn. J. Clin. Oncol. 30, 547\u2013552 (2000).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"37696_CR40","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1097\/JU.0000000000000688","volume":"203","author":"RL Steinberg","year":"2020","unstructured":"Steinberg, R. L. et al. Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J. Urol. 203, 902\u2013909 (2020).","journal-title":"J. Urol."},{"key":"37696_CR41","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.juro.2012.10.068","volume":"189","author":"LJ Barlow","year":"2013","unstructured":"Barlow, L. J., McKiernan, J. M. & Benson, M. C. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous Bacillus Calmette-Gu\u00e9rin therapy. J. Urol. 189, 834\u2013839 (2013).","journal-title":"J. Urol."},{"key":"37696_CR42","doi-asserted-by":"publisher","first-page":"3715","DOI":"10.1002\/cncr.30219","volume":"122","author":"NB Desai","year":"2016","unstructured":"Desai, N. B. et al. Genomic characterization of response to chemoradiation in urothelial bladder cancer. Cancer 122, 3715\u20133723 (2016).","journal-title":"Cancer"},{"key":"37696_CR43","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","volume":"68","author":"ER Plimack","year":"2015","unstructured":"Plimack, E. R. et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur. Urol. 68, 959\u2013967 (2015).","journal-title":"Eur. Urol."},{"key":"37696_CR44","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921 (2005).","journal-title":"Nature"},{"key":"37696_CR45","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1158\/1535-7163.MCT-10-0994","volume":"10","author":"F Janku","year":"2011","unstructured":"Janku, F. et al. PIK3CA mutations in patients with advanced cancers treated with PI3K\/AKT\/mTOR axis inhibitors. Mol. Cancer Ther. 10, 558\u2013565 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"37696_CR46","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114\u20132120 (2014).","journal-title":"Bioinformatics"},{"key":"37696_CR47","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3389\/fgene.2014.00111","volume":"5","author":"UH Trivedi","year":"2014","unstructured":"Trivedi, U. H. et al. Quality control of next-generation sequencing data without a reference. Front Genet 5, 111 (2014).","journal-title":"Front Genet"},{"key":"37696_CR48","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"key":"37696_CR49","doi-asserted-by":"crossref","first-page":"11.10.1","DOI":"10.1002\/0471250953.bi1110s43","volume":"43","author":"GA Van der Auwera","year":"2013","unstructured":"Van der Auwera, G. A. et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinforma. 43, 11.10.1\u201311.10.33 (2013).","journal-title":"Curr. Protoc. Bioinforma."},{"key":"37696_CR50","doi-asserted-by":"publisher","unstructured":"Ciani, Y. et al. Allele-specific genomic data elucidate the role of somatic gain and copy-number neutral loss of heterozygosity in cancer. Cell Syst. https:\/\/doi.org\/10.1016\/j.cels.2021.10.001 (2021).","DOI":"10.1016\/j.cels.2021.10.001"},{"key":"37696_CR51","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1093\/nar\/gkn089","volume":"36","author":"F Demichelis","year":"2008","unstructured":"Demichelis, F. et al. SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines. Nucleic Acids Res. 36, 2446\u20132456 (2008).","journal-title":"Nucleic Acids Res."},{"key":"37696_CR52","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1002\/cpbi.81","volume":"67","author":"D Prandi","year":"2019","unstructured":"Prandi, D. & Demichelis, F. Ploidy- and purity-adjusted allele-specific DNA analysis using CLONETv2. Curr. Protoc. Bioinforma. 67, e81 (2019).","journal-title":"Curr. Protoc. Bioinforma."},{"key":"37696_CR53","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"37696_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren, W. et al. The ensembl variant effect predictor. Genome Biol. 17, 122 (2016).","journal-title":"Genome Biol."},{"key":"37696_CR55","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899\u2013905 (2010).","journal-title":"Nature"},{"key":"37696_CR56","doi-asserted-by":"publisher","first-page":"D687","DOI":"10.1093\/nar\/gkab1028","volume":"50","author":"M Gillespie","year":"2022","unstructured":"Gillespie, M. et al. The reactome pathway knowledgebase 2022. Nucleic Acids Res. 50, D687\u2013D692 (2022).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37696-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37696-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37696-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:13:45Z","timestamp":1681863225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37696-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,18]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["37696"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-37696-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1758183\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,18]]},"assertion":[{"value":"14 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2214"}}